American Association for Cancer Research
10780432ccr133059-sup-115770_2_supp_2846466_nj5qxx.png (24.18 kB)

Supplemental Table 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Download (24.18 kB)
posted on 2023-03-31, 18:29 authored by Katja Karjalainen, Diana E. Jaalouk, Carlos Bueso-Ramos, Laura Bover, Yan Sun, Akihiko Kuniyasu, Wouter H.P. Driessen, Marina Cardó-Vila, Cecilia Rietz, Amado J. Zurita, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes, George A. Calin, Erkki Koivunen, Wadih Arap, Renata Pasqualini

Supplemental Table 1. Features of synthesized analogs of BMTP-11 for drug-lead optimization.



Purpose: The IL11 receptor (IL11R) is an established molecular target in primary tumors of bone, such as osteosarcoma, and in secondary bone metastases from solid tumors, such as prostate cancer. However, its potential role in management of hematopoietic malignancies has not yet been determined. Here, we evaluated the IL11R as a candidate therapeutic target in human leukemia and lymphoma.Experimental Design and Results: First, we show that the IL11R protein is expressed in a variety of human leukemia– and lymphoma–derived cell lines and in a large panel of bone marrow samples from leukemia and lymphoma patients, whereas expression is absent from nonmalignant control bone marrow. Moreover, a targeted peptidomimetic prototype (termed BMTP-11), specifically bound to leukemia and lymphoma cell membranes, induced ligand–receptor internalization mediated by the IL11R, and resulted in a specific dose-dependent cell death induction in these cells. Finally, a pilot drug lead-optimization program yielded a new myristoylated BMTP-11 analogue with an apparent improved antileukemia cell profile.Conclusions: These results indicate (i) that the IL11R is a suitable cell surface target for ligand-directed applications in human leukemia and lymphoma and (ii) that BMTP-11 and its derivatives have translational potential against this group of malignant diseases. Clin Cancer Res; 21(13); 3041–51. ©2015 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager